BiolineRx

Oncology Therapeutic Pharmaceutical Candidates

Health Tech & Life Sciences
Public on TASE on Apr, 2007
Public on NASDAQ on Mar, 2014

Company Overview

Snapshot

Founded in April 2003, BioLineRx is a public clinical-stage biopharmaceutical company with 51–200 employees. The company has raised over $208.64 million across 18 funding rounds from 10 investors. In January 2025, BioLineRx announced a $10 million registered direct offering.

Business overview

BioLineRx is a clinical-stage biopharmaceutical company specializing in oncology. The company's core product pipeline includes BL-8040, a platform designed for various cancer and hematological indications, and AGI-134, a synthetic immunotherapy under development for solid tumors. BioLineRx systematically identifies, validates, and in-licenses therapeutic candidates that offer advantages over existing treatments or address unmet medical needs. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the broader healthcare and life sciences markets.

Strategic signal

In September 2025, BioLineRx Ltd. and Hemispherian AS established a joint venture to develop GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers. This collaboration, following FDA IND clearance for a Phase 1/2a study, signals BioLineRx's strategic expansion into novel therapeutic mechanisms and a commitment to addressing challenging oncology indications, which could significantly enhance its pipeline and market position.

Company Intelligence Q&A

What was a significant recent development for BioLineRx's pipeline?
In September 2025, BioLineRx Ltd. and Hemispherian AS formed a joint venture to develop GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers. This initiative follows FDA IND clearance for a Phase 1/2a study.
What was the outcome of the third quarter 2025 earnings call?
In November 2025, BioLineRx Ltd. reported its third quarter 2025 financial results and provided a corporate update, highlighting strategic advances.
What intellectual property milestone did BioLineRx achieve in November 2025?
In November 2025, BioLineRx announced the receipt of a USPTO Notice of Allowance for a key patent covering GLIX1, intended for treating a broad range of cancer types.
What was the most recent funding event for BioLineRx?
In January 2025, BioLineRx announced a $10 million registered direct offering.
What strategic partnership did BioLineRx enter into in November 2024?
In November 2024, BioLineRx and Ayrmid Ltd. entered into an exclusive license agreement to commercialize APHEXDA (motixafortide) through Gamida Cell Ltd. Highbridge Capital Management was a lead investor in this PIPE funding round.

External links